

ASLAN Pharma to present two posters on varlitinib at ASCO

17 May 2018 | News

At ASCO, ASLAN will present the study design of its ongoing global pivotal clinical trial of varlitinib



Singapore- ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced the online publication of two abstracts on *varlitinib* that have been accepted for presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, 1-5 June 2018.

Varlitinib is a highly potent pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. At ASCO, ASLAN will present the study design of its ongoing global pivotal clinical trial of *varlitinib*, the TREATmEnT OPPortunity (TREETOPP) study, as a second-line treatment of biliary tract cancer. No new data from the TREETOPP study will be disclosed.

In a second poster, new data will be presented from a Phase 1b study of *varlitinib* to determine the maximum tolerated dose in advanced solid tumours as combination therapy with paclitaxel. The recommended dose of *varlitinib* in combination with paclitaxel was found to be 300mg BID. *Varlitinib* showed efficacy in HER2+ metastatic breast cancer patients with some patients experiencing relatively long durations of response. The study was conducted by Dr. Soo-Chin Lee (National University Cancer Institute, Singapore) in collaboration with ASLAN.